Biotech firm Regenxbio Q2 net loss widens
I'm PortAI, I can summarize articles.
Biotech firm Regenxbio reported a Q2 net loss of $70.9 million, up from $53.0 million last year, with revenues falling to $21.4 million due to decreased Zolgensma royalties. The company expects a cash runway into early 2027 and is accelerating pivotal trial enrollment for RGX-202. Increased R&D expenses were noted, driven by manufacturing and clinical trials. Analysts maintain a "buy" rating, with a median 12-month price target of $31.50, significantly above its recent closing price of $8.23.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments